March 5 - MODERNA (MRNA, Financial) secured a major legal win in its COVID-19 vaccine patent dispute with Pfizer (PFE, Financial) and BioNTech (BNTX, Financial). A Dusseldorf court ruled in favor of Moderna, according to a Wednesday court filing.
The court ruled that Pfizer and BioNTech must disclose any revenue gained from Moderna's patented technology, although the amount remains to be determined, and that they will pay extra.
Pfizer and BioNTech exercised legal authorization to use their patent until May 2023. The court made a decision that Moderna legally withdrew their consent in March 2022 so their previous patent permission became void. Legal analysts view the court decision as a major advancement within pharmaceutical intellectual property rights that affects the industry.
Industry stakeholders and investors now watch closely for further updates in this high-stakes patent conflict.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.